Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Polasek

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
F1000Research|November 23, 2019
Precision medicine technology hype or reality? The example of computer-guided dosingThomas M Polasek, Sepehr Shakib, Amin Rostami-Hodjegan
Expert Review of Clinical Pharmacology|July 17, 2018
Precision dosing in clinical medicine: present and futureThomas M Polasek, Sepehr Shakib, Amin Rostami-Hodjegan
Therapeutic Advances in Drug Safety|August 2, 2014
Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1Thomas M Polasek, Matthew P Doogue, John O Miners
Journal of Psychiatry & Neuroscience : JPN|May 12, 2023
Consistent terminology for medication-related problems in pharmacogenomic casesThomas M Polasek, Sam Mostafa, Carl M J Kirkpatrick
Thrombosis and Haemostasis|May 4, 2012
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleedingMichael J Sorich, Thomas M Polasek, Michael D Wiese
F1000Research|February 9, 2022
Attitudes of healthy volunteers to genetic testing in phase 1 clinical trialsSebastian Levesque, Thomas M Polasek, Eric Haan, et al.
Current Protocols in Toxicology|October 10, 2012
Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitroThomas M Polasek, David J Elliot, John O Miners
Therapeutic Advances in Drug Safety|June 2, 2018
Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacyThomas M Polasek, Matthew P Doogue, Tilenka R J Thynne
Therapeutic Advances in Drug Safety|December 20, 2019
Precision dosing to avoid adverse drug reactionsThomas M Polasek, Carl M J Kirkpatrick, Amin Rostami-Hodjegan
Molecular Genetics and Metabolism|December 19, 2023
First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adultsCecile Paquet Luzy, Emilie Doppler, Thomas M Polasek, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
F1000Research|November 23, 2019
Precision medicine technology hype or reality? The example of computer-guided dosingThomas M Polasek, Sepehr Shakib, Amin Rostami-Hodjegan
Expert Review of Clinical Pharmacology|July 17, 2018
Precision dosing in clinical medicine: present and futureThomas M Polasek, Sepehr Shakib, Amin Rostami-Hodjegan
Therapeutic Advances in Drug Safety|August 2, 2014
Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1Thomas M Polasek, Matthew P Doogue, John O Miners
Journal of Psychiatry & Neuroscience : JPN|May 12, 2023
Consistent terminology for medication-related problems in pharmacogenomic casesThomas M Polasek, Sam Mostafa, Carl M J Kirkpatrick
Thrombosis and Haemostasis|May 4, 2012
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleedingMichael J Sorich, Thomas M Polasek, Michael D Wiese
F1000Research|February 9, 2022
Attitudes of healthy volunteers to genetic testing in phase 1 clinical trialsSebastian Levesque, Thomas M Polasek, Eric Haan, et al.
Current Protocols in Toxicology|October 10, 2012
Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitroThomas M Polasek, David J Elliot, John O Miners
Therapeutic Advances in Drug Safety|June 2, 2018
Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacyThomas M Polasek, Matthew P Doogue, Tilenka R J Thynne
Therapeutic Advances in Drug Safety|December 20, 2019
Precision dosing to avoid adverse drug reactionsThomas M Polasek, Carl M J Kirkpatrick, Amin Rostami-Hodjegan
Molecular Genetics and Metabolism|December 19, 2023
First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adultsCecile Paquet Luzy, Emilie Doppler, Thomas M Polasek, et al.
Pageof 8